Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

6.12
-0.1700-2.70%
Volume:876.62K
Turnover:5.36M
Market Cap:839.32M
PE:-1.60
High:6.26
Open:6.22
Low:6.01
Close:6.29
Loading ...

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (Easl) Congress 2025

THOMSON REUTERS
·
24 Apr

Vir Biotechnology Is Maintained at Buy by Goldman Sachs

Dow Jones
·
18 Apr

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple

Insider Monkey
·
09 Apr

Pharma Stocks Sink After Trump Says "Major" Tariffs Are Coming

Tiger Newspress
·
09 Apr

Pharma Stocks Survive Market Rout on Tariff Exemption, but Uncertainty Continues

Reuters
·
03 Apr

Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution

Simply Wall St.
·
31 Mar

Pharma Stocks Sink After Ouster of Top FDA Vaccine Regulator

Reuters
·
31 Mar

BRIEF-Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection

Reuters
·
13 Mar

Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial

MT Newswires Live
·
13 Mar

Vir Biotechnology Enrolls First Patient in Phase 3 Eclipse Registrational Program for Chronic Hepatitis Delta

THOMSON REUTERS
·
13 Mar

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Business Wire
·
13 Mar

CrowdStrike Fuels Partner Growth and Profitability with Expanded Accelerate Partner Program

Business Wire
·
11 Mar

Vir Biotechnology Is Maintained at Overweight by Barclays

Dow Jones
·
01 Mar

Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Barclays Remains a Buy on Vir Biotechnology (VIR)

TIPRANKS
·
28 Feb

Stock Track | Vir Biotechnology Plummets 9.46% as Key Pipeline Programs Remain Early-Stage

Stock Track
·
28 Feb

Q4 2024 Vir Biotechnology Inc Earnings Call

Thomson Reuters StreetEvents
·
28 Feb

Stock Track | Vir Biotechnology Soars 5.98% on Strong Q4 Results and Promising Outlook

Stock Track
·
27 Feb

Vir Biotechnology Price Target Maintained With a $19.00/Share by Needham

Dow Jones
·
27 Feb

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GuruFocus.com
·
27 Feb